Explore 3 Stock Ideas & Industry Insights Download Free Report

BeyondSpring Inc

Company price
0.6012 USD 0.00 ( 0.03%)
Last update at 2026-11-13T21:00:00Z
VOLUME
31868
Market Cap
71.55M

Momentum Score

…

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.59
Low
0.63
High
52 Week Price Range
1.21
Low
3.44
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BeyondSpring Inc is a clinical-stage biopharmaceutical company developing oncology therapies, with a lead small-molecule candidate, plinabulin, targeting prevention of chemotherapy-induced neutropenia and potential immunomodulatory benefits in cancer treatment. Long-term growth drivers include successful clinical validation in registrational studies, expansion into combination oncology indications and potential commercialization or licensing arrangements that may benefit revenue prospects.

Principal risks include trial failure or safety issues, high cash burn requiring additional financing, manufacturing and supply challenges, and competition from established supportive-care biologics and other oncology agents that could limit market adoption.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.60
Dividend Yield
-
Revenue TTM
1.88M
Revenue Per Share
0.05
Gross Profit TTM
1.35M
Debt / Equity
-0.01
ROE
-310.48%
Net Debt
-7.47M
ROCE
-72.39%
Diluted EPS TTM
-0.21

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.62M -8.77M -13.92M -36.12M -64.64M
Minority interest 13.21M 5.57M 0.92M 3.00M 4.03M
Net income -7.99M -11.12M -21.03M -36.28M -68.21M
Selling general administrative 4.56M 6.11M 10.23M 13.01M 30.70M
Selling and marketing expenses - - 0.30M - -
Gross profit -0.09M -0.28M -0.30M 1.35M 1.35M
Reconciled depreciation 0.09M 0.28M 0.30M 0.23M 0.06M
Ebit -8.95M -8.75M -13.92M -37.24M -66.24M
Ebitda -8.86M -8.47M -13.62M -35.44M -64.72M
Depreciation and amortization 0.09M 0.28M 0.30M 1.80M 1.52M
Operating income -8.95M -8.75M -15.08M -37.24M -66.24M
Other operating expenses 8.95M 8.75M 15.08M 38.59M 67.59M
Interest expense - - 0.00M 0.02M 0.09M
Tax provision 0.09M 0.10M 0.11M 0.16M 3.57M
Interest income 0.08M 0.06M 0.42M 0.20M 0.10M
Net interest income 0.08M 0.06M 0.42M 0.18M 0.01M
Income tax expense 0.09M 0.10M 0.09M 0.16M 3.57M
Total revenue 0.00M 0.00M 1.75M 1.35M 1.35M
Total operating expenses 8.86M 8.75M 14.78M 38.59M 67.59M
Cost of revenue 0.09M 0.28M 0.30M - -
Total other income expense net 0.32M -0.01M 1.16M 1.12M 1.60M
Net income from continuing ops -8.71M -8.87M -21.95M -36.28M -68.21M
Net income applicable to common shares - - - - -64.18M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 25.93M 34.31M 24.81M 46.22M 81.65M
Other current assets 8.32M 25.66M 0.48M 0.76M 1.02M
Total liab 49.92M 48.60M 48.27M 49.23M 60.73M
Total stockholder equity -32.16M -32.90M -26.80M -5.98M 26.68M
Other current liab -15.71M -16.97M 4.17M 3.95M 10.02M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -408.43M -407.43M -396.30M -375.28M -342.00M
Other liab - - - - 38.65M
Other assets - - 0.00M - 3.12M
Cash 7.79M 2.92M 17.75M 34.40M 41.62M
Total current liabilities 13.58M 11.01M 7.96M 7.35M 15.15M
Current deferred revenue 28.60M 27.40M 1.75M 1.35M 1.37M
Net debt -7.47M -2.33M -13.76M -29.43M -38.05M
Short term debt 0.32M 0.28M 0.63M 0.97M 2.11M
Short long term debt - - - - 1.57M
Short long term debt total 0.32M 0.59M 4.00M 4.96M 3.58M
Other stockholder equity 375.66M 373.19M 368.60M 368.86M 369.20M
Property plant equipment - - - - 3.41M
Total current assets 20.88M 28.58M 18.42M 38.52M 75.12M
Net tangible assets - - - - 26.68M
Short term investments 4.78M 0.00M 0.19M 2.87M 30.74M
Accounts payable 0.36M 0.29M 1.41M 1.08M 1.66M
Accumulated other comprehensive income 0.60M 1.34M 0.89M 0.44M -0.52M
Non currrent assets other 4.58M 4.99M 0.36M 0.35M 1.57M
Non current assets total 5.05M 5.74M 6.39M 7.70M 6.53M
Capital lease obligations 0.32M 0.59M 4.00M 4.96M 2.01M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 3.48M -12.01M -0.10M 17.56M -20.41M
Change to liabilities - - - 0.00M 29.47M
Total cashflows from investing activities 13.48M -12.01M -0.10M - -20.41M
Net borrowings 0.29M 3.91M 0.00M - -
Total cash from financing activities 2.27M 26.79M 0.00M 3.43M 0.00M
Change to operating activities - - - 7.09M 0.19M
Net income -14.22M -11.12M -21.03M -36.28M -68.21M
Change in cash 4.86M -1.70M -16.65M -7.23M -67.91M
Begin period cash flow 16.05M 17.75M 34.40M 41.62M 109.54M
End period cash flow 7.79M 16.05M 17.75M 34.40M 41.62M
Total cash from operating activities -20.02M -16.44M -16.47M -27.46M -47.24M
Issuance of capital stock 2.00M 3.00M 0.00M 0.00M 0.00M
Depreciation 0.09M 0.28M 0.30M 0.23M 0.06M
Other cashflows from investing activities 7.30M -11.79M - - -
Change to inventory -0.02M -0.02M 0.19M - 1.77M
Other cashflows from financing activities 4.97M 22.87M 0.00M 5.00M 0.00M
Change to netincome - - - - -1.53M
Capital expenditures 0.05M 0.22M 0.10M 0.03M 2.84M
Change in working capital -0.38M -1.38M 2.71M 6.41M 18.41M
Stock based compensation 0.72M 2.06M 0.55M 1.67M 3.15M
Other non cash items -6.24M -6.29M 0.99M 0.51M 0.55M
Free cash flow -20.07M -16.67M -16.57M -27.50M -50.09M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BYSI
BeyondSpring Inc
0.00
0.03%
0.60 - 10.54 45.99 5.38 41.79 0.05
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

BeyondSpring Inc

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

100 Campus Drive, Florham Park, NJ, United States, 07932

646 305 6387

44

Name Title Year Born
Dr. Lan Huang Co-Founder, Chairman & CEO 1971
Dr. G. Kenneth Lloyd Chief Scientific Officer 1944
Dr. Ramon W. Mohanlal Exec. VP of R&D, Chief Medical Officer and Director 1958
Mr. Linqing Jia Co-Founder NA
Stephen Kilmer Head of Investor Relations NA
Mr. Gregg Russo Sr. VP of HR NA
Dr. Lan Huang Ph.D. Co-Founder, Chairman & CEO 1971
Dr. June Lu Ph.D. Chief Scientific Officer NA
Mr. Gregg Russo Senior Vice President of Human Resources NA
Dr. June Lu Ph.D. Chief Scientific Officer 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…